Partial Epigenetic Reprogramming

Partial epigenetic reprogramming and stem cell transplantation both trace back to the same scientific discovery, Shinya Yamanaka's identification of four transcription factors that can reset a cell's epigenetic state, but they are different therapeutic strategies with different goals, different safety profiles, and different regulatory pathways. This page exists specifically to draw that distinction clearly, since marketing materials sometimes blur the two.

Stem cell transplantation, covered throughout the rest of this encyclopedia section, introduces new cells into a patient's body, whether bone marrow stem cells, MSCs, or lab-grown islet cells, to replace or supplement existing tissue function. Partial epigenetic reprogramming does not transplant anything. It applies the same Yamanaka factors, or related reprogramming signals, briefly and partially to a person's own existing cells in place, with the goal of resetting age-related epigenetic changes, such as DNA methylation patterns, without pushing the cell all the way back to a pluripotent, embryonic-like state [1]. Full reprogramming to pluripotency, the process used to make iPSCs, erases a cell's identity entirely and carries a meaningful tumor risk if it happens in a living body rather than a lab dish. Partial reprogramming is designed deliberately to stop short of that point, aiming to erase age-related epigenetic marks while preserving the cell's original identity and function.

The foundational peer-reviewed evidence for this mechanism comes from mouse studies showing that cyclic, short-duration expression of Yamanaka factors in vivo can reverse several molecular and cellular hallmarks of aging without causing loss of cell identity or tumor formation in the treated tissues studied [2]. This established the biological plausibility of the partial reprogramming approach and set off a wave of well-funded private research aimed at translating it into a human therapy.

Altos Labs, a heavily capitalized biotechnology company focused specifically on cellular rejuvenation, has reported eighteen-month primate safety data at scientific conferences, including presentations describing no teratoma formation, no abnormal cell proliferation, and no evidence of off-target reprogramming in treated animals, alongside epigenetic clock measurements suggesting a multi-year reduction in estimated biological age [3]. As of this writing, this primate dataset has been presented at conferences and covered in industry press rather than published in a peer-reviewed journal with its own citable paper, so it should be treated as preliminary company-reported data pending independent peer review, distinct from the peer-reviewed mouse mechanism study cited above [3][4].

Life Biosciences has moved further into human testing with ER-100, a partial reprogramming therapy targeting optic neuropathies including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The FDA cleared the company's investigational new drug application for ER-100 in January 2026, which the company and independent trade coverage described as the first cellular rejuvenation therapy based on partial epigenetic reprogramming to reach human clinical testing [5][6]. Life Biosciences announced dosing of the first patient in June 2026 [7]. This is a Phase 1 safety and dose-finding trial; it has not yet generated efficacy data, and no partial reprogramming therapy is approved anywhere as of mid-2026.

The optic nerve target is a deliberate choice: the eye offers a contained, directly observable tissue where researchers can assess whether reprogramming affects vision without needing to reprogram cells throughout the whole body, making it a comparatively conservative first step for a technology whose long-term safety profile in humans remains completely unknown. Given that this entire approach has exactly one Phase 1 human trial underway and only mouse-level peer-reviewed mechanism data, it sits in tier 4 of our evidence framework, the same category as untested-in-humans hypotheses that have at least some published mechanistic biology behind them, one step above pure speculation. Readers should not confuse a partial-reprogramming product, if one is ever marketed, with an established MSC or HSC stem cell therapy; the biology, safety questions, and regulatory history are entirely separate.